LakeShore Biopharma Co., Ltd announced the completion of its going private transaction, merging with a subsidiary of Oceanpine Skyline Inc. The merger, approved by shareholders on June 19, 2026, results in LakeShore becoming a wholly owned subsidiary of Parent and ceasing to be a publicly traded company. Shareholders will receive US$0.066 per share in cash, and the company will file a Form 15 with the SEC to suspend its reporting obligations.
This move is significant because it removes LakeShore from the public eye, allowing it to pursue long-term strategic goals without the scrutiny of quarterly earnings reports. The company, which focuses on vaccines and therapeutic biologics for infectious diseases and cancer, can now redirect resources from compliance and investor relations to research and development. The PIKA® immunomodulating technology platform remains a key asset, and private ownership may accelerate its clinical and commercial applications.
The transaction was advised by Kroll, LLC for the Special Committee, with Gibson, Dunn & Crutcher LLP and Maples and Calder (Hong Kong) LLP as legal counsel. White & Case LLP represented the buyer group. LakeShore expects its trading symbols to be removed from the OTC Pink tier, cautioning that any trades after the merger effective time will be invalid.
For more information about LakeShore Biopharma, visit https://investors.lakeshorebio.com/.
